Compare ADMA Biologics Inc (ADMA) vs Harley-Davidson Inc (HOG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Harley-Davidson Inc — how do they compare? ADMA Biologics Inc trades at $9.18 (market cap $2.13B), while Harley-Davidson Inc trades at $25.32 (market cap $2.73B). The key difference: Harley-Davidson Inc is the larger of the two by market cap, and Harley-Davidson Inc pays a 2.84% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | HOG | |
|---|---|---|
Market Cap | $2.13B | $2.73B |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $31.03 |
52-Week Low | $7.60 | $17.19 |
Enterprise Value | $2.20B | $3.12B |
Dividend Yield | — | 2.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Harley-Davidson (HOG) trades at $25.89, up 3.73% today, with mixed technical signals showing bullish moving averages but neutral oscillators. Fundamentally, the company faces revenue declines from $5.8B in 2022 to $4.5B in 2025, though valuation ratios remain attractive with P/E of 13.12 and P/B of 0.87. Recent Q1 2026 earnings missed expectations at $0.22 vs. $0.34, but Q2 results are anticipated on July 23, 2026. Positive developments include production returning to the US and cost-cutting initiatives.
The outlook is cautious with analyst consensus at Hold (65.71%) and price target of $23.20 below current price. Risks include ongoing margin pressure, competitive threats, and execution of turnaround plans. Upside potential exists if cost savings and US production boost profitability, but investors should monitor Q2 earnings for confirmation of operational improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Harley-Davidson Inc
Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →
